Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)
/PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has...
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Lille, France; Cambridge, MA; July 08, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives...
GENFIT: May 25, 2022 Combined Shareholders Meeting results
Quorum of 25.16% on first convening; allowing approval of all the resolutions submitted by the Board of Directors Lille, France; Cambridge, MA; May 25,...
GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)
Cash and cash equivalents totaled €222.2 million as of March 31, 2022 Lille, France; Cambridge, MA; May 11, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a...